piclidenoson pivotal is a Can-Fite BioPharma Ltd. program in moderate-to-severe plaque psoriasis. Its next catalyst is a Readout in Q1 2027.
All upcoming FDA decision dates on the 2026 PDUFA calendar
Indication under review: moderate-to-severe plaque psoriasis. Sponsor: Can-Fite BioPharma Ltd. (CANF). We track 1 catalyst event for this program: 1 upcoming and 0 in the record. A PDUFA date is the FDA's target date to complete review of a marketing application; a readout is the sponsor's expected date for clinical trial results. What a PDUFA date is · why we do not compare trial results across drugs.
The next tracked catalyst for piclidenoson pivotal is a Readout in Q1 2027.
No FDA decision for piclidenoson pivotal is in our archive yet.
In our records piclidenoson pivotal is under review or in development for moderate-to-severe plaque psoriasis.
Can-Fite BioPharma Ltd. (CANF).
FDA announcements, sponsor press releases and SEC filings. Each FDA decision links its own page, which names its source or says plainly that it has none.